Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GSK's long-acting injection beats Truvada in HIV prevention trial

05/18/2020 | 08:07am EDT
Outbreak of the coronavirus disease (COVID-19) in London

By Ludwig Burger

GlaxoSmithKline said an injection every other month of its cabotegravir drug was shown to avert an HIV infection more effectively than Gilead's daily Truvada pill, potentially giving its ViiV unit a foothold in HIV prevention.

The drug trial involving men who have sex with men was stopped early by an independent monitoring board after cabotegravir was found to be 69% more effective than the current standard of care, Truvada, the British drugmaker said on Monday.

But the market segment GSK is eyeing is about to become more competitive as cheaper generic versions of Truvada are expected to be launched in the United States in September, as the patent expires.

Gilead, for its part, hopes that Truvada users will opt against the cheaper copies and switch to its new daily pill Descovy, approved in October 2019 after it was shown to be less toxic to the kidneys and bones.

Truvada generated $2.8 billion (£2.31 billion) in sales last year, both from treatment and preventing an HIV infection.

Kimberly Smith, ViiV's head of research, said a long-acting injection was a better route of administer because users have shown to struggle with a strict routine of daily pills, heightening the infection risk.

"Individuals have to show up every eight weeks in the clinic for the injection but in-between there is not a need to take a pill daily, so you really change the equation for adherence with a long acting (drug)," Smith said.

GSK, which is trailing Gilead in the HIV treatment market, will speak to drug regulators about a possible approval of cabotegravir based on the prevention trial, a spokesman said.

Its shares were up 1.25% at 1120 GMT, outperforming a 0.8% gain in the STOXX Europe 600 Health Care

Prevention "has turned into a multi-billion opportunity for Gilead but we think consensus estimates include little or nothing for GSK in this market," UBS analysts said in a research note.

GSK has won approval in Canada for cabotegravir as one of two key ingredients in long-acting HIV treatment combination Cabenuva, whereas in the United States, the company has run into delays seeking the go-ahead for Cabenuva.

An initial readout from the trial, which started in late 2016, was previously not expected before next year.

A similar trial to test the cabotegravir injection to prevent HIV in women, is still ongoing.

Pfizer and Shionogi & Co Ltd hold small stakes in GSK's HIV-focused ViiV Healthcare division.

(Reporting by Ludwig Burger, editing by Louise Heavens)

ę Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
BYD COMPANY LIMITED -6.34% 204 End-of-day quote.0.39%
CHANGE INC. -0.48% 2684 End-of-day quote.-23.86%
GILEAD SCIENCES, INC. 0.26% 68.93 Delayed Quote.18.31%
GLAXOSMITHKLINE PLC -0.02% 1404.2 Delayed Quote.4.26%
PFIZER, INC. 0.69% 42.1 Delayed Quote.14.37%
SHIONOGI & CO., LTD. -0.34% 5950 End-of-day quote.5.59%
STOXX EUROPE 600 0.38% 460.42 Delayed Quote.14.94%
STOXX EUROPE 600 NR 0.38% 1030.68 Delayed Quote.16.73%
SWITCH, INC. -0.72% 20.55 Delayed Quote.25.53%
UBS GROUP AG 0.00% 14.845 Delayed Quote.19.05%
All news about GILEAD SCIENCES, INC.
07/27INSIDER TRENDS : Insider at Gilead Sciences Acquires Stock Via Option/Derivative..
07/21GILEAD SCIENCES : Statement on Positive Phase 3 AMBITION Study Findings for the ..
07/20BIONTECH : to Acquire Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufa..
07/20ARCUS BIOSCIENCES : Chief Medical Officer Resigns to Join Gilead's Oncology Team
07/20PRESS RELEASE : Japan becomes first country to approve Ronapreve (casirivimab an..
07/19ADRs End Lower; Toyota, BioNTech Among Companies Actively Trading
07/19Health Care Down Amid Defensive Bias -- Health Care Roundup
07/19GILEAD SCIENCES : BioNTech to Buy Gilead Sciences Unit's Cell Therapy R&D Platfo..
07/19GILEAD SCIENCES : New Phase 3 Data Support the Sustained, Long-Acting Efficacy o..
07/19GILEAD SCIENCES : Four-Year Biktarvy Data Presented at IAS 2021 Demonstrate High..
More news
Financials (USD)
Sales 2021 24 671 M - -
Net income 2021 6 917 M - -
Net Debt 2021 21 993 M - -
P/E ratio 2021 13,1x
Yield 2021 4,10%
Capitalization 86 451 M 86 451 M -
EV / Sales 2021 4,40x
EV / Sales 2022 4,34x
Nbr of Employees 13 600
Free-Float 99,9%
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | MarketScreener
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 31
Last Close Price 68,93 $
Average target price 75,07 $
Spread / Average Target 8,91%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE248.38%68 592
WUXI APPTEC CO., LTD.28.80%64 659
GENMAB A/S11.86%28 658